Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is a T cell reprogramming company specializing in developing innovative T cell therapies for patients with solid tumors. The company's technology platforms, including Gen-R and Epi-R, enable the development of T cell therapies to overcome exhaustion and generate durable stemness. Their pipeline includes LYL797 for non-small cell lung cancer and triple negative breast cancers, LYL845 targeting multiple solid tumors, and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Additionally, the company has entered into a research and development collaboration and license agreement with GlaxoSmithKline for the NY-ESO-1 program.

Products

• T cell therapies for solid tumors